Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
05/2010
05/05/2010EP1414486B1 Use of glp-2 in combination with another therapeutic agent in bone-related disorders
05/05/2010EP1248803B1 Nogo receptor-mediated blockade of axonal growth
05/05/2010EP1060261B1 Poly zinc finger proteins with improved linkers
05/05/2010EP0946185B2 PHARMACEUTICAL COMPOSITION COMPRISING A COMPOUND HAVING ANTI-Xa ACTIVITY AND A PLATELET AGGREGATION ANTAGONIST COMPOUND
05/05/2010EP0854917B1 Transgenic non-human animals capable of producing heterologous antibodies
05/05/2010EP0703783B1 Methods of making immunogenic hla-a2.1 binding peptides
05/05/2010CN1994464B ACEI inhibitor and application thereof
05/05/2010CN1976947B Biologically active peptide VAPEEHPTLLTEAPLNPK derivatives
05/05/2010CN1958794B Method for preparing mutant code cDNA of apoptosis induction ligand related to human tumor necrosis factor, and application
05/05/2010CN1947792B Method for preparing active protein composition type nano-selenium and its liquid phase storage tech.
05/05/2010CN1922314B Fungall cell wall degrading enzyme
05/05/2010CN1902217B Novel peptide, process for producing the same and pharmaceutical composition containing the peptide
05/05/2010CN1816353B Medicinal composition for preventing or treating Th1 type immunological disease
05/05/2010CN1799627B Natto kinase oral liquid and its manufacturing method
05/05/2010CN1787820B Composition for improving cognition and memory
05/05/2010CN1785425B Preparation method of poly peptide vaccine for treating lefteye flounder adenolymphocele
05/05/2010CN1630526B Systems and methods for treating patients with processed lipoaspirate cells
05/05/2010CN1446261B Modified cytokines for use in cancer therapy
05/05/2010CN1420924B Recombinant human alpha-L-iduronidase, method for producing and purifying same and method for treating disorders including deficiency thereof
05/05/2010CN101701032A Quinoxalinone low molecular weight peptide derivative with matrix metalloproteinases inhibition function and preparation method and application thereof
05/05/2010CN101700401A Polyalkylene glycol with moiety for conjugating biologicallyactive compound
05/05/2010CN101700233A Method for preparing gonadorelin freeze-dried powder injection
05/04/2010US7709630 hybridizable with nucleic acids encoding connective tissue growth factor to modulate the expression of connective tissue growth factor in cells; diabetes
05/04/2010US7709621 Vectors with modified protease-dependent tropism
05/04/2010US7709617 Derivatized with a glycerol linker, 2'-deoxy-7-deazaguanosine and arabinoguanosine; immunomer is self-complementary; anticarcinogenic, antiinflammatory, antiallergen, antihistamine, and bronchodilator agents; asthma, skin disorders
05/04/2010US7709609 Tumor suppressor gene, p47ING3
05/04/2010US7709607 solubility of the variant is improved by at least 3-fold relative to residues 110-244 of human adiponectin; increased soluble expression and stability, lower immunogenicity, and improved pharmacokinetics and/or pharmacodynamics
05/04/2010US7709601 Nylon binding peptides and methods of use
05/04/2010US7709600 Interaction between the VHL tumor suppressor and hypoxia inducible factor, and assay methods relating thereto
05/04/2010US7709529 Treatment of cancer with glutamine
05/04/2010US7709460 co-administration of a glutathione precursor (N-acetyl cysteine or alpha -lipoic acid) and hydroxocobalamin (a derivative of Vitamin B12) to patients with a functional Vitamin B12 deficiency and suffering from a neuropsychiatric abnormality
05/04/2010US7709455 administering a VEGFR modulating agent that comprises placental growth factor; a growth factor that binds and activates Flt-1 such as PIGF or VEGF-B, an anti-Flt-1 agonistic antibody or a small molecule agonist
05/04/2010US7709452 Pharmaceutical composition which improves in vivo gene transfer
05/04/2010US7709451 Method and composition for treating immune complex associated disorders
05/04/2010US7709450 Stimulation of vascularization with VEGF-B-186
05/04/2010US7709446 Multifunctional protease inhibitors and their use in treatment of disease
05/04/2010US7709445 Colloidal suspension of nanoparticles based on an amphiphilic copolymer
05/04/2010US7709444 Echinocandin pharmaceutical formulations containing micelle-forming surfactants
05/04/2010US7709443 For treatment of human melanoma, pancreatic, breast, prostate cancer cells
05/04/2010US7709442 In vivo synthesis of connective tissues
05/04/2010US7709441 Using carbonic anhydrase related protein (CARP) as tool in treatment and prevention of calcium release disorders
05/04/2010US7709439 one bioactive polymer comprised of at least one peptide and/or protein subunit and at least one polysaccharide and/or proteoglycan subunit; and biocompatible polymer; providing a scaffold for cell migration and attachment
05/04/2010US7709270 Using platelete derived growth factor as tool in detection of modulators for prevention and treatment of cell proliferative disorders
05/04/2010US7709228 Single-chain polypeptide fusion comprising functional binding, translocation and clostridial neurotoxin heavy chain domain for use as therapeutic agents and/or transporter molecules
05/04/2010US7709220 Methods of monitoring treatment of BAFF-R related disease
05/04/2010US7709218 Tumor necrosis factor receptors 6α and 6β
05/04/2010US7709217 Mixture comprising hemopoietic cytokine specific immunnoglobulin for use in detection of infection and immunololgical disorders
05/04/2010US7709211 Proteins expressed by mycobacterium tuberculosis and not by BCG and their use as diagnostic reagents and vaccines
05/04/2010US7709031 Angiogenic agents from plant extracts, gallic acid, and derivatives
05/04/2010US7709017 Biocompatible, biodegradable globins modified by acetylation, succinylationor esterification; soluble at physioloical pH; grafting; powder, granules, film, membrane, mesh, sponge and preformed implant, or in paste, gel, or suspension form; prosthetics
05/04/2010US7709008 An recombinant serine-aspartate repeat (Sdr) protein from Staphylococcus epidermidis which is cell-wall associated, wherein the protein comprises the amino acid sequence 10-1742 of SEQ ID NO: 4.; multicomponent vaccines; coating polymericbiomaterials; catheters; prosthetics; nucleic acid probes
05/04/2010US7709006 Hepatitis-C virus testing
05/04/2010US7709004 Method of producing an HIV-1 immune response
05/04/2010US7709003 Method of producing an HIV-1 immune response
05/04/2010US7709000 Using MG1(mucin) specific immunoglobulins to target therapeutic agents to tumor cells
05/04/2010US7708998 Methods of inhibiting unwanted cell proliferation using hedgehog antagonists
05/04/2010US7708996 Tumor necrosis factor receptor specific immunoglobulins for use in treatment and prevention of cancers, autoimmune, viral, inflammatory, graft vs host and nervous system disorders
05/04/2010US7708995 Use of TNF-alpha inhibitors for treating a nerve disorder mediated by nucleus pulposus
05/04/2010US7708990 used in maintaining a blood coenzyme Q concentration at a high level in blood for a prolonged period of time
05/04/2010US7708989 Administering nitrosated angiotensin converting enzyme inhibitors and other nitrosated compounds for cardiovascular disorders and treatment of hypertensive agents
05/04/2010US7708987 ras-mediated; administering immunosuppressive for immune constituents that may interfere with the systemic delivery of the reovirus; antiproliferative; in the neoplastic cells phosphorylation of PKR is prevented by inactivation or deletion of PKR; antitumor agents
05/04/2010US7708986 Targeted vectors for cancer immunotherapy
05/04/2010US7708985 Glycosylated IL-7, preparation and uses
05/04/2010US7708984 Using immunoglobulin specific to adenoid expressed chemokine (ADEC) for prevention and treatment of cell proliferative, glandular and viral infection
05/04/2010US7708983 Directional induction of immune response by co-administration of antigens with chemokines
05/04/2010US7708978 Water-solubility macromolecule conjugate with interferon; polyoxyethylene glycol, polyoxypropylene glycol or copolymers; one end group having a glucose attached, the other an interferon; long physiological cycle half-life; bioavailability; binds to asialoglycoprotein receptors on liver; hepititis B/C
05/04/2010CA2448863C Increased and sustained in vivo gene expression using a nucleic acid, histone, and amphipathic compound composition
05/04/2010CA2427385C Nutritional composition for an immune condition
05/04/2010CA2418395C Protein induced by homogeneous blood transfusion and dna encoding the same
05/04/2010CA2412880C Glutamine fructose-6-phosphate amidotransferase splice variant and its expression product
05/04/2010CA2406202C Whitening compositions containing ascomycete derived enzyme
05/04/2010CA2367636C Fusion proteins
05/04/2010CA2347178C Methods of inhibiting smooth muscle cell proliferation and preventing restenosis with a vector expressing rb2/p130
05/04/2010CA2319057C Compositions comprising a poly(oxyethylene)-poly(oxypropylene) block copolymer and their use
05/04/2010CA2318494C Angiotensin converting enzyme inhibitor
05/04/2010CA2281920C Compositions and methods for modulating cellular nf-.kappa.b activation
05/04/2010CA2221568C Metabolic effects of certain glutathione analogs
05/04/2010CA2172398C Methods and products for controlling immune responses in mammals
05/04/2010CA2158134C Supplemented tissue sealant
05/04/2010CA2140638C Generation of xenogeneic antibodies
05/04/2010CA2089376C Sugar modified oligonucleotides that detect and modulate gene expression
05/04/2010CA1341604C Dna sequences, recombinant dna molecules and processes for producing human fibroblast interferon-like polypeptides
04/2010
04/29/2010WO2010048625A1 Active agents, compositions, and methods for inhibiting and reversing platelet function
04/29/2010WO2010048610A2 Compositions and methods for promoting bone formation
04/29/2010WO2010048601A1 Biodefenses using triazole-containing macrolides
04/29/2010WO2010048481A1 Nutritional composition to promote healthy development and growth
04/29/2010WO2010048476A1 Methods for determining the bioactivity of tgf-beta in a composition
04/29/2010WO2010048468A1 Deuterated macrocyclic inhibitors of viral ns3 protease
04/29/2010WO2010048446A2 Modulation of axon degeneration
04/29/2010WO2010048365A2 Therapeutic peptide bioconjugates
04/29/2010WO2010048340A2 Novel semi-synthetic glycopeptides as antibacterial agents
04/29/2010WO2010048308A2 Natriuretic polypeptides
04/29/2010WO2010048298A1 Combination therapy with peptide epoxyketones
04/29/2010WO2010048275A2 Lyophilized recombinant vwf formulations
04/29/2010WO2010048125A2 Compositions and methods for inhibiting the interaction between cftr and cal
04/29/2010WO2010047717A1 Stable, water-insoluble r-(+)-alpha-lipoic acid salt useful for the treatment of diabetes mellitus and its co-morbidities
04/29/2010WO2010047714A1 Cancer therapy
04/29/2010WO2010047493A2 Composition for the treatment of cancer, containing a kir 2.2 inhibitor
04/29/2010WO2010047028A1 Screening method of anti-lung or esophageal cancer compounds
04/29/2010WO2010046867A1 A fusion protein having antitumor activity
1 ... 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 ... 3163